跳至主要内容
临床试验/NCT04486638
NCT04486638招募中不适用

Dengvaxia US Pregnancy Registry: A Surveillance Study to Assess the Safety of Dengvaxia Among Exposed Pregnant Women and Their Offsprings (DNG00044)

Sanofi Pasteur, a Sanofi Company1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
1
主要终点
Percentage of pregnant women with maternal adverse events

研究概览

简要总结

The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy

详细描述

Exposed pregnant women will be followed up to the end of their pregnancy, and the offspring(s) will be followed up to 1 year of age.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • The eligible population will include pregnant women of any age and their offspring(s) residing in the US and its Territories whose Dengvaxia pregnancy exposure is reported to the pregnancy registry.
  • Reports of Dengvaxia pregnancy exposure must contain the following information to be included in the registry:
  • Sufficient evidence to confirm the case qualifies as "exposed during pregnancy";
  • Vaccine name (brand or generic) is provided (i.e., including manufacturer unknown exposures).
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

排除标准

  • 未提供

研究组 & 干预措施

Pregnant women and their offspring(s)

Women and their offspring(s) exposed to Dengvaxia during pregnancy

干预措施: Dengue Tetravalent Vaccine, Live (Biological)

结局指标

主要结局

Percentage of pregnant women with maternal adverse events

时间窗: From vaccination until end of follow-up (maximum 22 months after cohort entry)

Maternal adverse events are reported as serious or non-serious

Pecentage of women with obstetrical adverse events

时间窗: From vaccination until 1 month post-delivery

Obstetrical adverse events are collected during pregnancy, labour, delivery and puerperium, and are reported as serious or non-serious

Percentage of participants with adverse pregnancy outcome

时间窗: On day of birth

Adverse pregnancy outcomes include ectopic pregnancy, elective/induced abortion with no fetal defect(s) or fetus status unknown, elective/induced abortion with fetal defect(s), spontaneous abortion/miscarriage (\<20 weeks), stillbirth/fetal death at 20-27 weeks, fetal death at ≥28 weeks, and fetal death due to maternal death

Percentage of offsprings with infant adverse events

时间窗: From 29 days to 365 days post-birth

Infant events are reported as serious or non-serious

Percentage of offsprings with neonatal adverse events

时间窗: From day of birth to 28 days post-birth

Neonatal events are reported as serious or non-serious

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验